VIDEO: AHA includes ‘exciting’ early research on HF treatments
In this video, Nancy K. Sweitzer, MD, PhD, director of the University of Arizona Sarver Heart Center and professor of medicine and chief of the division of cardiology at the University of Arizona College of Medicine, Tucson, discusses the types of research presented on HF at this year’s American Heart Association Scientific Sessions.
Sweitzer noted that presentations on HF from the meeting “fall into two buckets.”
She said one included small, early-stage studies on novel therapeutics, noting that “it’s always exciting at the AHA meeting to see what types of therapy might be coming down the pike,” but added that more studies are needed before these options affect clinical practice.
The other “bucket” of HF presentations, according to Sweitzer, consisted of studies that “affirm current practice or changing practice,” which included data presented on SGLT2 inhibitors.
“There were a lot of trials presented that added to the body of knowledge about the benefit of SGLT2 inhibitors in heart failure, and the data continue to increase that this is likely independent of injection fraction,” Sweitzer said. “Although, questions linger about whether there’s an injection fraction that’s too high to benefit from these agents.”